Dr. Heinz Lenz, MD | Los Angeles, CA ...

Dr. Warren A. Chow

Claim this profile

City of Hope Comprehensive Cancer Center

Studies Melanoma
Studies Cancer
13 reported clinical trials
31 drugs studied

Area of expertise

1

Melanoma

Warren A. Chow has run 5 trials for Melanoma. Some of their research focus areas include:

Stage IV
Stage III
BRAF positive
2

Cancer

Warren A. Chow has run 3 trials for Cancer. Some of their research focus areas include:

Stage IV
NY-ESO-1 positive
HLA-A positive

Affiliated Hospitals

Image of trial facility.

UC Irvine Health/Chao Family Comprehensive Cancer Center

Image of trial facility.

City Of Hope Comprehensive Cancer Center

Clinical Trials Warren A. Chow is currently running

Image of trial facility.

TAB004 + Toripalimab

for Solid Cancers

The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.

Recruiting

1 award

Phase 1

10 criteria

Image of trial facility.

Neoadjuvant Daromun + Surgery

for Melanoma

The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery and adjuvant therapy).

Recruiting

2 awards

Phase 3

18 criteria

More about Warren A. Chow

Clinical Trial Related

6 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical Trials

Treatments Warren A. Chow has experience with

  • Nivolumab
  • Ipilimumab
  • GSK Adoptive Cell Therapy
  • Fludarabine
  • Cyclophosphamide
  • Letetresgene Autoleucel (lete-cel, GSK3377794)

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Warren A. Chow specialize in?

Is Warren A. Chow currently recruiting for clinical trials?

Are there any treatments that Warren A. Chow has studied deeply?

What is the best way to schedule an appointment with Warren A. Chow?

What is the office address of Warren A. Chow?

Is there any support for travel costs?